Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7079057 | 0.80 | KDM1A (0.50) | KDM1ASLC6A3SLC6A4 | |
| SCHEMBL3024025 | 0.79 | HSD11B1 (0.59) | HSD11B1 | |
| SCHEMBL18905254 | 0.76 | HSD11B1 (0.39) | HSD11B1 | |
| SCHEMBL6891957 | 0.76 | HSD11B1 (0.54) | MAOAMAOBKDM1AHSD11B1SLC6A3 | |
| SCHEMBL6899610 | 0.76 | HSD11B1 (0.54) | MAOAMAOBHSD11B1SLC6A3SLC6A4 | |
| SCHEMBL6896759 | 0.75 | HSD11B1 (0.53) | HSD11B1 | |
| SCHEMBL6901003 | 0.75 | MAOA (0.41) | MAOAMAOBKDM1AHSD11B1SLC6A3 | |
| Hydrochloric Acid SCHEMBL6897921 | 0.73 | SLC6A3 (0.46) | MAOAMAOBKDM1AHSD11B1SLC6A3 | |
| SCHEMBL7078035 | 0.71 | HSD11B1 (0.40) | HSD11B1 | |
| SCHEMBL16687335 | 0.71 | ALDH1A1 (0.39) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1143964-B1 | 2-ADAMANTANEMETHANAMINE COMPOUNDS FOR TREATING ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RES LTD (GB) | 2004-03-24 | — | — | EP | disclosed |
| US-6531511-B1 | N-methyl aspartate receptor antagonist | VERNALIS RESEARCH LIMITED (GB) | 2003-03-11 | — | — | US | disclosed |
| EP-1143964-A1 | 2-ADAMANTANEMETHANAMINE COMPOUNDS FOR TREATING ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RESEARCH LIMITED (GB) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000044371-A1 | 2-ADAMANTANEMETHANAMINE COMPOUNDS FOR TREATING ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RESEARCH LIMITED (GB) | 2000-08-03 | — | — | WO | disclosed |